Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Shares Outstanding (Weighted Average): 2016-2024

Historic Shares Outstanding (Weighted Average) for Protagonist Therapeutics (PTGX) over the last 9 years, with Dec 2024 value amounting to $59.6 million.

  • Protagonist Therapeutics' Shares Outstanding (Weighted Average) rose 5.61% to $62.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.2 million, marking a year-over-year increase of 5.61%. This contributed to the annual value of $59.6 million for FY2024, which is 3.33% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Shares Outstanding (Weighted Average) of $59.6 million as of FY2024, which was up 3.33% from $57.7 million recorded in FY2023.
  • Protagonist Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $59.6 million for FY2024, and its period low was $38.3 million during FY2020.
  • Over the past 3 years, Protagonist Therapeutics' median Shares Outstanding (Weighted Average) value was $57.7 million (recorded in 2023), while the average stood at $55.5 million.
  • Data for Protagonist Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 40.62% (in 2020) over the last 5 years.
  • Protagonist Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $38.3 million in 2020, then climbed by 24.76% to $47.7 million in 2021, then increased by 3.08% to $49.2 million in 2022, then grew by 17.24% to $57.7 million in 2023, then increased by 3.33% to $59.6 million in 2024.